Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$33.39 USD
-0.96 (-2.79%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $33.39 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Protagonist Therapeutics, Inc. [PTGX]
Reports for Purchase
Showing records 1 - 20 ( 50 total )
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
JNJ-2113 Continues to Show Its Worth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Strong Balance Sheet Ensure Pipeline Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Blockbuster Partnership for Protagonist as Takeda Inks Deal for Rusfertide; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
JNJ Raise the Bar for JNJ-2113 at Analyst Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
JNJ-2113 Stands Apart and Rusfertide Plows Ahead Without Missing a Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Update: Assets Gain Recognition as Balance Sheet Gains Strength; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
JNJ-2113 Looks to Be a Winner From Our Vantage Point
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EHA Presentation Showcases Efficacy of Rusfertide; Additional Extension Study Announced; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Data Increase Our Confidence in Multiple Assets; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Protagonist Therapeutics; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Positive Data for Rusfertide Continues to Mount; Raise PT to $38; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protagonist Stands to Gain as FRONTIER Delivers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It Might Take a Little Longer to VERIFY Rusfertide in PV Though We Remain Bullish; PT Down to $33; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rusfertide Remains the Focus as PN-943 To Be Advanced With a Partner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
When Less is More as PN-943 Shows a Strong Signal at Lower Dose; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Has Second Thoughts on Breakthrough Designation for Rusfertide; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protagonist?s Diverse Pipeline Moving Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Update From ASH: Rusfertide Continues to Dramatically Reduce TP Need, Now in High HCT Patients Too; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D